Sanofi and Regeneron report positive results from Phase 2 study with alirocumab

Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) said the first Phase 2 study with alirocumab, an investigational monoclonal antibody targeting PCSK9 or proprotein convertase subtilisin/kexin type 9, in Japanese patients met its primary endpoint. The results demonstrated that the mean low-density lipoprotein-cholesterol percentage reduction from baseline to week 12, the primary efficacy endpoint of the study, was significantly greater in patients randomized to receive one of three doses of alirocumab administered every other week -- 150 milligrams, or mg, 75 mg, and 50 mg, in combination with statin therapy, compared to patients receiving placebo.